Currency in GBP
Last close As at 09/06/2023
GBP0.25
▲ 2.00 (8.60%)
Market capitalisation
GBP89m
Research: Healthcare
Creo Medical has announced the signing of a non-exclusive licence and royalty agreement with a global surgical robotics company, CMR Surgical, providing further momentum to an already busy FY22. Under the terms of the agreement, CMR will be permitted to integrate certain features of Creo’s Kamaptive technology into its Versius surgical robotic system, a next-generation laparoscopic surgery robot.
The details of the licence and royalty agreement remain undisclosed, but the deal represents another win for the company’s ‘Powered by Kamaptive’ licensing programme after a collaboration with Intuitive Surgical was announced in May 2022. We view the new agreement as strengthening Creo’s offering in the surgical robotics sector and believe it could hold upside potential if development is successful. When specifics of the agreement are made public, we will revisit our valuation.
Creo Medical |
Second robotics deal signed |
Licence and royalty agreement |
Healthcare equipment & services |
25 October 2022 |
Share price performance Business description
Analysts
Creo Medical is a research client of Edison Investment Research Limited |
Creo Medical has announced the signing of a non-exclusive licence and royalty agreement with a global surgical robotics company, CMR Surgical, providing further momentum to an already busy FY22. Under the terms of the agreement, CMR will be permitted to integrate certain features of Creo’s Kamaptive technology into its Versius surgical robotic system, a next-generation laparoscopic surgery robot. The details of the licence and royalty agreement remain undisclosed, but the deal represents another win for the company’s ‘Powered by Kamaptive’ licensing programme after a collaboration with Intuitive Surgical was announced in May 2022. We view the new agreement as strengthening Creo’s offering in the surgical robotics sector and believe it could hold upside potential if development is successful. When specifics of the agreement are made public, we will revisit our valuation.
Year end |
Revenue |
PBT* (£m) |
EPS* |
DPS |
P/E |
Yield |
12/20 |
9.4 |
(23.0) |
(12.8) |
0.0 |
N/A |
N/A |
12/21 |
25.2 |
(29.7) |
(14.6) |
0.0 |
N/A |
N/A |
12/22e |
28.7 |
(25.8) |
(12.1) |
0.0 |
N/A |
N/A |
12/23e |
33.8 |
(23.7) |
(11.1) |
0.0 |
N/A |
N/A |
Note: *PBT and EPS are normalised, excluding amortisation of acquired intangibles, exceptional items and share-based payments.
CMR’s Versius robotic-surgery system is currently being used by surgeons worldwide for laparoscopic procedures in areas including gynaecology, colorectal surgery, thoracic surgery, general surgery and urology. Following the May 2022 collaboration with category leader Intuitive Surgical (a US-based medical robotics developer for minimally invasive procedures), we view the CMR agreement as further validation for Creo’s technology offering.
In addition to the new CMR agreement and existing Intuitive Surgical collaboration, Creo has entered into non-binding terms with a number of parties to provide third-party access via potential licensing deals to its advanced energy Kamaptive technology (specifically for SpydrBlade, Cool Plasma and MicroBlate). These agreements are an effort by management to develop a potential market in additional surgical areas, such as laparoscopic surgery, robotic-assisted surgery and non-thermal plasma sterilisation, where Creo does not currently have operational presence.
In May 2022 Creo entered into a long-term agreement with Intuitive Surgical to optimise certain Creo products to be compatible with Intuitive Surgical’s robotic technology. The agreement entails joint regulatory studies prior to approval, which can take up to 18 months. The first ‘upfront’ payment was recorded in this update although the specifics were not disclosed. While we await further details on deal terms, we believe both of these agreements reinforces the company’s differentiated offering and Creo could be entitled to potential royalties and milestones.
|
|
Since its launch in March 2012 to end-September 2022, Premier Miton Global Renewables Trust’s (PMGR) share price has returned over 250%. During the past 12 months the performance has been very volatile, and the manager, James Smith, has responded by restructuring the portfolio away from Chinese holdings towards higher-yielding UK and European companies. Smith believes that as energy security concerns will result in governments and companies signing long-term contracts with renewable energy producers in the UK and Europe, the share prices of renewable companies should start to stabilise.
Get access to the very latest content matched to your personal investment style.